Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | HRAS over exp |
Therapy | Tipifarnib + Uprosertib |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
HRAS over exp | head and neck squamous cell carcinoma | predicted - sensitive | Tipifarnib + Uprosertib | Preclinical - Pdx | Actionable | In a preclinical study, Zarnestra (tipifarnib) and Uprosertib (GSK2141795) combination treatment resulted in enhanced tumor regression in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma overexpressing wild-type Hras (J Clin Oncol 38: 2020 (suppl; abstr e15658)). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated HNSCC. | Full reference... |